BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24695356)

  • 21. Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum.
    Boehr S; Haen E
    Ther Drug Monit; 2017 Feb; 39(1):66-76. PubMed ID: 27861316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
    Wong PC; White A; Luettgen J
    Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
    Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
    Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.
    Kuhn J; Gripp T; Flieder T; Dittrich M; Hendig D; Busse J; Knabbe C; Birschmann I
    PLoS One; 2015; 10(12):e0145478. PubMed ID: 26699714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
    Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
    Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
    Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
    J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
    Lim MS; Chapman K; Swanepoel P; Enjeti AK
    Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
    Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
    Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and validation of an ultra-high performance liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of direct oral anticoagulants in human plasma.
    Zhang YF; Liu XQ; Wang Y; Xu X; Zhong MK; Zhang P; Ma CL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122952. PubMed ID: 34598085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.